We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
+6.76%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$324M
AUM Growth
+$50M
Cap. Flow
-$4.14M
Cap. Flow %
-1.28%
Top 10 Hldgs %
80.32%
Holding
49
New
10
Increased
8
Reduced
14
Closed
15

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$7.06M
2
ABT icon
Abbott
ABT
+$4.8M
3
MCK icon
McKesson
MCK
+$4.23M
4
BDX icon
Becton Dickinson
BDX
+$3.81M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$3.65M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$7.25M
2
DCGO icon
DocGo
DCGO
+$4.17M
3
VTRS icon
Viatris
VTRS
+$2.39M
4
ASND icon
Ascendis Pharma A/S
ASND
+$2.14M
5
RDNT icon
RadNet
RDNT
+$2.08M

Sector Composition

Rank Sector Weight
1 Miscellaneous 59.34%
2 Healthcare 40.41%
3 Consumer Staples 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$815B
$175M 54.16%
400,000
+300,000
+300% +$126M
TLT icon
2
CALL
iShares 20+ Year Treasury Bond ETF
TLT
$46.6B
$15.4M 4.77%
+150,000
New +$15.6M
VTRS icon
3
Viatris
VTRS
$19.4B
$12.5M 3.86%
1,250,000
-250,000
-17% -$2.39M
MDRX
4
DELISTED
Veradigm Inc. Common Stock
MDRX
$11.7M 3.62%
930,000
-20,000
-2% -$243K
PHR icon
5
Phreesia
PHR
$679M
$8.99M 2.78%
290,000
-30,000
-9% -$939K
COLL icon
6
Collegium Pharmaceutical
COLL
$766M
$8.06M 2.49%
375,000
+20,000
+6% +$454K
THC icon
7
Tenet Healthcare
THC
$21.3B
$7.73M 2.39%
95,000
-5,000
-5% -$356K
TCMD icon
8
Tactile Systems Technology
TCMD
$495M
$7.48M 2.31%
300,000
-60,000
-17% -$1.25M
BMRN icon
9
BioMarin Pharmaceuticals
BMRN
$12.9B
$6.5M 2.01%
+75,000
New +$7.06M
STRM
10
DELISTED
Streamline Health Solutions
STRM
$6.26M 1.94%
328,725
– –
MCK icon
11
McKesson
MCK
$106B
$5.98M 1.85%
14,000
+11,000
+367% +$4.23M
SIBN icon
12
SI-BONE Inc
SIBN
$829M
$5.4M 1.67%
200,000
-75,000
-27% -$1.83M
SNY icon
13
Sanofi
SNY
$106B
$5.12M 1.58%
95,000
– –
ABT icon
14
Abbott
ABT
$187B
$4.91M 1.52%
+45,000
New +$4.8M
ANGO icon
15
AngioDynamics
ANGO
$628M
$4.85M 1.5%
465,000
-10,000
-2% -$96.2K
RDNT icon
16
RadNet
RDNT
$5.8B
$4.57M 1.41%
140,000
-71,500
-34% -$2.08M
CERS icon
17
Cerus
CERS
$522M
$4.3M 1.33%
1,750,000
-500,000
-22% -$1.19M
ATRC icon
18
AtriCure
ATRC
$2.62B
$4.2M 1.3%
85,000
+44,624
+111% +$2.06M
BDX icon
19
Becton Dickinson
BDX
$50.3B
$3.96M 1.22%
+15,000
New +$3.81M
TEVA icon
20
Teva Pharmaceuticals
TEVA
$42.4B
$3.39M 1.05%
+450,000
New +$3.65M
ALKS icon
21
Alkermes
ALKS
$7.73B
$3.13M 0.97%
100,000
+25,000
+33% +$757K
INMD icon
22
InMode
INMD
$858M
$2.8M 0.87%
75,000
-40,000
-35% -$1.4M
IRWD icon
23
Ironwood Pharmaceuticals
IRWD
$704M
$2.39M 0.74%
225,000
+15,000
+7% +$161K
DXCM icon
24
DexCom
DXCM
$33.2B
$2.06M 0.64%
+16,000
New +$1.94M
RIGL icon
25
Rigel Pharmaceuticals
RIGL
$909M
$1.61M 0.5%
125,000
-75,000
-38% -$1.01M
1
2

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q2 2023 Portfolio in Review

As of Q2 2023, Tamarack Advisers held 49 positions worth $324M, up 18% from $274M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Tamarack Advisers's Q2 2023 filing shows 10 new, 8 increased, 14 reduced and 15 closed positions. Its largest new stake was BioMarin Pharmaceuticals: 75,000 shares worth $6.5M. The largest sale was Amgen, an estimated $7.25M.

By sector, the portfolio is most concentrated in Miscellaneous at 59% of assets, up from 52% a quarter earlier, followed by Healthcare and Consumer Staples.

  • Tamarack Advisers's largest Q2 2023 buy was BioMarin Pharmaceuticals: 75,000 shares worth $6.5M.
  • Tamarack Advisers added most to McKesson in Q2 2023, an estimated $4.23M increase.
  • Tamarack Advisers's biggest Q2 2023 reduction was DocGo, cutting an estimated $4.17M.
  • Tamarack Advisers fully exited Amgen in Q2 2023, selling an estimated $7.25M.
  • Tamarack Advisers's ten largest holdings make up 80% of its $324M portfolio in Q2 2023.
  • Tamarack Advisers opened 10 new positions and closed 15 in Q2 2023.
  • Tamarack Advisers's portfolio value rose 18% quarter-over-quarter to $324M.

Based on Tamarack Advisers's 13F filing for Q2 2023, filed 10 Aug 2023.